Original article
L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis

https://doi.org/10.1016/j.mayocp.2013.02.007Get rights and content

Abstract

Objective

To evaluate the effects of L-carnitine compared with placebo or control on morbidity and mortality in the setting of acute myocardial infarction.

Methods

A systematic review and meta-analysis of 13 controlled trials (N=3629) was conducted to determine the effects of L-carnitine vs placebo or control on mortality, ventricular arrhythmias (VAs), angina, heart failure, and reinfarction. These trials were identified via searches of the Ovid MEDLINE, PubMed, and Excerpta Medica (Embase) databases between May 1, 2012, and August 31, 2012.

Results

Compared with placebo or control, L-carnitine was associated with a significant 27% reduction in all-cause mortality (odds ratio, 0.73; 95% CI, 0.54-0.99; P=.05; risk ratio [RR], 0.78; 95% CI, 0.60-1.00; P=.05), a highly significant 65% reduction in VAs (RR, 0.35; 95% CI, 0.21-0.58; P<.0001), and a significant 40% reduction in the development of angina (RR, 0.60; 95% CI, 0.50-0.72; P<.00001), with no reduction in the development of heart failure (RR, 0.85; 95% CI, 0.67-1.09; P=.21) or myocardial reinfarction (RR, 0.78; 95% CI, 0.41-1.48; P=.45).

Conclusion

Compared with placebo or control, L-carnitine is associated with a 27% reduction in all-cause mortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an acute myocardial infarction. Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted.

Section snippets

Methods

We performed a systematic review of the available literature according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines for the conduct of systematic reviews of intervention studies.10

Identification and Selection of Studies

The literature search yielded 153 titles, of which 18 were reviewed in full text on the basis of the inclusion criteria. Of these, 13 studies were deemed eligible for inclusion (Figure 1).4, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 Supplemental Tables 1 and 2 (available online at http://www.mayoclinicproceedings.org) summarize the characteristics of the included studies and the risk of bias in the included trials.4, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 Supplemental Table 3

Discussion

This systematic review of 13 controlled trials in 3629 patients involving 250 deaths, 220 cases of new HF, and 38 recurrent myocardial infarctions found that the use of L-carnitine was associated with a significant reduction in all-cause mortality and a highly significant reduction in VAs and anginal attacks.

The potential mechanisms responsible for the observed beneficial impact of L-carnitine in AMI are likely multifactorial and may, in part, be conferred through the ability of L-carnitine to

Conclusion

Compared with placebo or control, L-carnitine is associated with a 27% reduction in all-cause mortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an AMI. Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted.

References (34)

  • P. Colonna et al.

    Myocardial infarction and left ventricular remodeling: results of the CEDIM trial

    Am Heart J

    (2000)
  • Y.Y. Bai et al.

    L-Carnitine and cardiovascular disease: from basic science to clinical application

    Cardiology

    (2009)
  • H.D. White et al.

    Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction

    Circulation

    (1987)
  • A. Liberati et al.

    The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

    BMJ

    (2009)
  • J.P. Higgins et al.

    Quantifying heterogeneity in a meta-analysis

    Stat Med

    (2002)
  • P. Davini et al.

    Controlled study on L-carnitine therapeutic efficacy in post-infarction

    Drugs Exp Clin Res

    (1992)
  • Cited by (161)

    • L-carnitine: Nutrition, pathology, and health benefits

      2023, Saudi Journal of Biological Sciences
    • Exchanges between the gastrointestinal system and the brain

      2023, Introduction to Quantitative EEG and Neurofeedback: Third Edition
    • Plasma L-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study

      2022, Nutrition, Metabolism and Cardiovascular Diseases
      Citation Excerpt :

      For example, in an experimental study with hypercholesterolaemic rabbits, daily administration of l-carnitine for 28 days completely prevented the progression of atherosclerotic lesions in both aorta and coronaries [23]. A meta-analysis studies including 13 controlled trials showed that compared with placebo or control group, l-carnitine was associated with a 27% reduction in all-cause mortality, a 65% reduction in ventricular arrhythmias, and a 40% reduction in anginal symptoms in patients experiencing an acute myocardial infarction [11]. However, the predictive significance of circulating l-carnitine levels on subsequent cardiovascular events in the setting of ischemic stroke remains unclear.

    View all citing articles on Scopus
    View full text